
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
A Case of Platinum-Sensitive Epithelial Ovarian Cancer
A 49-Year-Old Woman with Platinum-Sensitive Epithelial Ovarian Cancer and GermlineBRCA1Mutation
March 2013
September 2015
November 2017






